key: cord-0811098-e2hlp1h9
authors: Felices-Farias, Jose Manuel; Martínez-Martínez, Juan Francisco; Guzmán-Aroca, Florentina
title: Adenopatías con características de malignidad secundarias a la vacuna BNT162b2 mRNA Covid-19
date: 2021-06-16
journal: Med Clin (Barc)
DOI: 10.1016/j.medcli.2021.06.002
sha: 4c58d017543fa23b0d8fd44c02ab99b4b6a0bc54
doc_id: 811098
cord_uid: e2hlp1h9

nan

BNT162b2 mRNA Covid-19 vaccine has proved to be effective and safe. Nevertheless, the pathologist report disclosed benignity, so an alternative diagnosis must be investigated. The common event shared by all these patients was the recent BNT162b2 mRNA Covid-19 vaccination ipsilateral to the identified lymphadenopathies. The relationship between the axillary lymphadenopathy and the BNT162b2 mRNA Covid-19 vaccine is plausible owing to the early immune response in the first nodes which receive the pathogen after its inoculation 1 .

Furthermore, this relationship is highly probable according to the reports in the efficacy and safety studies about SARS-CoV-2 and other pathogens vaccines 1, 4 in which the reported histological appearance was also similar to benign reactive lymphadenopathies 5 .

The lymphadenopathies are expected to disappear within ten days after BNT162b2 mRNA Covid-19 vaccination 1 . Similar benign evolution of reactive lymphadenopathies is shown posterior to other vaccines 4 .

The current vaccination process against Covid-19 demands the clinicians to expect the potential lymphadenopathy occurrence, even in asymptomatic patients or unusual locations as the supraclavicular region, and the radiologists to know its delicate sonographic appearance. We consider this information to be urgent according to prevent false positives, unnecessary lymph node biopsies and patient concern.

To conclude, we would like to suggest: 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

National Comprehensive Cancer Network (2021) Breast Cancer Screening and Diagnosis

Pre-operative staging of the axilla in primary breast cancer. By redefining the abnormal appearing node can we reduce investigations without affecting overall treatment?

A statistical analysis of vaccine-adverse event data